| Name | Atogepant |
| Description | Atogepant (MK-8031) is an orally available, selective and potent calcitonin gene-related peptide receptor (CGRP) antagonist for the study of migraine. |
| In vitro | Atogepant has a CGRP IC50=0.026 nM for human clones.
The binding affinities of Atogepant for human and non-human CGRP receptors were: human (cloned) Ki=0.015 nM, human (natural) Ki=0.026 nM, rhesus macaque Ki=0.009 nM, rat Ki=0.7 nM, mouse Ki=0.13 nM, rabbit Ki=2.1 nM, dog Ki=1.2 nM, respectively. [1][2] |
| In vivo | Oral administration of Atogepant to rats (at doses of 3, 10, and 30 mg/kg, respectively) once daily for 9 days showed that Atogepant effectively attenuated the abnormal facial pain induced by nitroglycerin and ameliorated the capsaicin-induced vasodilation of primate dermis in rats.[2] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (132.56 mM), Sonication is recommended.
|
| Keywords | MK8031 | CGRPReceptor | CGRP Receptor | CGRP | Atogepant |
| Inhibitors Related | HCGRP-(8-37) acetate | Olcegepant | Cagrilintide | SUN B8155 | Ubrogepant | Rimegepant | Calcitonin(salmon) Acetate(47931-85-1(free base)) | Adrenomedullin (AM) (22-52), human acetate | Vazegepant | β-CGRP, human acetate | Cagrilintide acetate | BCTC |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Approved Drug Library | Membrane Protein-targeted Compound Library | Drug-induced Liver Injury (DILI) Compound Library | EMA Approved Drug Library | Toxic Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library |
United States
